Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody –drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
ConclusionsAMG 595 exhibited favorable pharmacokinetics and is a unique therapy with possible benefit for some patients with EGFRvIII-mutated GBM with limited therapeutic options.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Glioma | Neurology | Study | Thrombocytopenia | Toxicology